Aktienanalyse zu Sunshine Biopharma Inc (SBFM)SBFMSunshine Biopharma Inc

Sunshine Biopharma Inc. is a pharmaceutical company engaged in offering and researching life-saving medicines in a variety of therapeutic areas, including oncology and antivirals. The Company has approximately 70 generic prescription drugs on the market in Canada. In addition, the Company is conducting a proprietary drug development program which is comprised of K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and PLpro protease inhibitor, a small molecule for the treatment of SARS Coronavirus infections. The Company operates through two segments: Prescription Generic Pharmaceuticals (Generic Pharmaceuticals) and Nonprescription Over-The-Counter Products (OTC Products). The Company operates two wholly owned subsidiaries: Nora Pharma Inc., which has a portfolio of pharmaceutical products consisting of various prescription drugs on the market in Canada, and Sunshine Biopharma Canada Inc., which develops and sells nonprescription over-the-counter (OTC) products. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Sunshine Biopharma Inc (SBFM) appears to be a good buy right now due to its recent surge in stock price by 66% following drug approval and a reverse stock split, indicating strong market optimism. The current price is $1.15, and despite a year-to-date decline of 91.02%, the projected final change based on historical patterns suggests a potential upside of 121.43%. However, the main risk is the negative earnings per share (EPS) of -1.15 reported in the last earnings, which reflects ongoing financial challenges.